Ellen L Goode

List of Publications by Citations

140 papers	6,545 citations	40 h-index	77 g-index
149 ext. papers	8,162 ext. citations	8.1 avg, IF	4.48 L-index

#	Paper	IF	Citations
140	Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. *Lancet Oncology, The*, **2012**, 13, 385-94	21.7	612
139	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. *Nature Genetics*, **2013**, 45, 371-84, 384e1-2	36.3	422
138	A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. *Nature Genetics*, **2010**, 42, 874-9	36.3	277
137	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. *Nature Genetics*, **2013**, 45, 362-70, 370e1-2	36.3	267
136	A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. *Nature Genetics*, **2009**, 41, 996-1000	36.3	240
135	Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. *Journal of the National Cancer Institute*, **2014**, 106,	9.7	215
134	Common variants at 19p13 are associated with susceptibility to ovarian cancer. *Nature Genetics*, **2010**, 42, 880-4	36.3	210
133	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nature Genetics*, **2017**, 49, 680-691	36.3	190
132	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nature Genetics*, **2015**, 47, 164-71	36.3	177
131	Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. *JAMA Oncology*, **2017**, 3, e173290	13.4	152
130	Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. *Journal of the National Cancer Institute*, **2014**, 106, djt431	9.7	149
129	Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. *Endocrine-Related Cancer*, **2013**, 20, 251-62	5.7	135
128	Cancer Risks Associated With Germline Pathogenic Variants: An International Study of 524 Families. *Journal of Clinical Oncology*, **2020**, 38, 674-685	2.2	133
127	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. *Nature Communications*, **2013**, 4, 1628	17.4	124
126	PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. *Journal of Medical Genetics*, **2016**, 53, 800-811	5.8	121
125	HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer. *Genome Medicine*, **2015**, 7, 108	14.4	110
124	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. *Cancer Discovery*, **2016**, 6, 1052-67	24.4	104

123	A functional variant in HOXA11-AS, a novel long non-coding RNA, inhibits the oncogenic phenotype of epithelial ovarian cancer. *Oncotarget*, **2015**, 6, 34745-57	3.3	92
122	The contribution of deleterious germline mutations in BRCA1, BRCA2 and the mismatch repair genes to ovarian cancer in the population. *Human Molecular Genetics*, **2014**, 23, 4703-9	5.6	90
121	A review of the application of inflammatory biomarkers in epidemiologic cancer research. *Cancer Epidemiology Biomarkers and Prevention*, **2014**, 23, 1729-51	4	88
120	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. *Nature Communications*, **2013**, 4, 1627	17.4	85
119	Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk. *Nature Communications*, **2014**, 5, 5303	17.4	84
118	IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer. *Cancer Research*, **2017**, 77, 6667-6678	10.1	79
117	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. *International Journal of Epidemiology*, **2016**, 45, 1619-1630	7.8	77
116	Identification of nine new susceptibility loci for endometrial cancer. *Nature Communications*, **2018**, 9, 3166	17.4	70
115	Consortium analysis of 7 candidate SNPs for ovarian cancer. *International Journal of Cancer*, **2008**, 123, 380-388	7.5	66
114	Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes. *Clinical Cancer Research*, **2017**, 23, 3794-3801	12.9	62
113	PD-1 Blunts the Function of Ovarian Tumor-Infiltrating Dendritic Cells by Inactivating NF-**B**. *Cancer Research*, **2016**, 76, 239-50	10.1	62
112	Epigenetics in ovarian cancer. *Seminars in Cancer Biology*, **2018**, 51, 160-169	12.7	57
111	Heritability of longitudinal measures of body mass index and lipid and lipoprotein levels in aging twins. *Twin Research and Human Genetics*, **2007**, 10, 703-11	2.2	56
110	Five endometrial cancer risk loci identified through genome-wide association analysis. *Nature Genetics*, **2016**, 48, 667-674	36.3	56
109	Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes. *Clinical Cancer Research*, **2017**, 23, 4077-4085	12.9	54
108	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. *Nature Communications*, **2016**, 7, 12675	17.4	53
107	Inherited determinants of ovarian cancer survival. *Clinical Cancer Research*, **2010**, 16, 995-1007	12.9	50
106	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. *Human Molecular Genetics*, **2015**, 24, 5955-64	5.6	48

105	Cross Cancer Genomic Investigation of Inflammation Pathway for Five Common Cancers: Lung, Ovary, Prostate, Breast, and Colorectal Cancer. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	47
104	Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. *Human Molecular Genetics*, **2015**, 24, 1478-92	5.6	46
103	Shared heritability and functional enrichment across six solid cancers. *Nature Communications*, **2019**, 10, 431	17.4	45
102	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. *International Journal of Epidemiology*, **2016**, 45, 884-95	7.8	45
101	Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2016**, 25, 1503-1510	4	42
100	Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. *Cancer Medicine*, **2018**, 7, 1978-1987	4.8	40
99	Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. *Journal of Pathology: Clinical Research*, **2018**, 4, 250-261	5.3	38
98	TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer. *Nucleic Acids Research*, **2015**, 43, 6945-58	20.1	37
97	Combined and interactive effects of environmental and GWAS-identified risk factors in ovarian cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2013**, 22, 880-90	4	37
96	Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer. *Cancer Immunology, Immunotherapy*, **2015**, 64, 1495-504	7.4	36
95	Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expression signatures. *Gynecologic Oncology*, **2016**, 141, 95-100	4.9	34
94	Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers. *Nature Communications*, **2020**, 11, 3353	17.4	32
93	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. *Cancer Research*, **2018**, 78, 5419-5430	10.1	32
92	Candidate gene analysis using imputed genotypes: cell cycle single-nucleotide polymorphisms and ovarian cancer risk. *Cancer Epidemiology Biomarkers and Prevention*, **2009**, 18, 935-44	4	31
91	Assessment of hepatocyte growth factor in ovarian cancer mortality. *Cancer Epidemiology Biomarkers and Prevention*, **2011**, 20, 1638-48	4	30
90	Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium. *British Journal of Cancer*, **2016**, 115, 95-101	8.7	28
89	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. *Cancer Research*, **2019**, 79, 505-517	10.1	28
88	Kernel canonical correlation analysis for assessing gene-gene interactions and application to ovarian cancer. *European Journal of Human Genetics*, **2014**, 22, 126-31	5.3	27

#	Reference		
87	Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1. *Scientific Reports*, **2015**, 5, 17369	4.9	27
86	Chronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk: Evidence from the Ovarian Cancer Association Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2016**, 25, 1114-24	4	27
85	Factors that influence survival in high-grade serous ovarian cancer: A complex relationship between molecular subtype, disease dissemination, and operability. *Gynecologic Oncology*, **2018**, 150, 227-232	4.9	26
84	Common Genetic Variation and Susceptibility to Ovarian Cancer: Current Insights and Future Directions. *Cancer Epidemiology Biomarkers and Prevention*, **2018**, 27, 395-404	4	25
83	Quantifying the Genetic Correlation between Multiple Cancer Types. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 1427-1435	4	25
82	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. *Clinical Cancer Research*, **2015**, 21, 5264-76	12.9	24
81	Xenobiotic-Metabolizing gene polymorphisms and ovarian cancer risk. *Molecular Carcinogenesis*, **2011**, 50, 397-402	5	24
80	EGFR as a prognostic biomarker and therapeutic target in ovarian cancer: evaluation of patient cohort and literature review. *Genes and Cancer*, **2017**, 8, 589-599	2.9	24
79	Tumor hypomethylation at 6p21.3 associates with longer time to recurrence of high-grade serous epithelial ovarian cancer. *Cancer Research*, **2014**, 74, 3084-91	10.1	23
78	Gene expression differences between matched pairs of ovarian cancer patient tumors and patient-derived xenografts. *Scientific Reports*, **2019**, 9, 6314	4.9	22
77	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). *Journal of Genetics and Genome Research*, **2015**, 2,		22
76	Genes associated with bowel metastases in ovarian cancer. *Gynecologic Oncology*, **2019**, 154, 495-504	4.9	21
75	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). *Clinical Cancer Research*, **2020**, 26, 5411-5423	12.9	21
74	Intraperitoneal disease dissemination patterns are associated with residual disease, extent of surgery, and molecular subtypes in advanced ovarian cancer. *Gynecologic Oncology*, **2017**, 147, 503-508	4.9	19
73	Inherited variants in regulatory T cell genes and outcome of ovarian cancer. *PLoS ONE*, **2013**, 8, e53903	3.7	19
72	Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer. *Oncotarget*, **2016**, 7, 6353-68	3.3	19
71	Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. *British Journal of Cancer*, **2017**, 116, 524-535	8.7	18
70	Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies. *International Journal of Cancer*, **2017**, 140, 2422-2435	7.5	18

69	Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. *Genetic Epidemiology*, **2015**, 39, 689-97	2.6	18
68	Comprehensive Cross-Population Analysis of High-Grade Serous Ovarian Cancer Supports No More Than Three Subtypes. *G3: Genes, Genomes, Genetics*, **2016**, 6, 4097-4103	3.2	18
67	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. *Human Genetics*, **2016**, 135, 741-56	6.3	18
66	Going to extremes: determinants of extraordinary response and survival in patients with cancer. *Nature Reviews Cancer*, **2019**, 19, 339-348	31.3	17
65	Drug discovery using clinical outcome-based Connectivity Mapping: application to ovarian cancer. *BMC Genomics*, **2016**, 17, 811	4.5	17
64	A Common Variant at the 14q32 Endometrial Cancer Risk Locus Activates AKT1 through YY1 Binding. *American Journal of Human Genetics*, **2016**, 98, 1159-1169	11	17
63	The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies. *Cancer Epidemiology*, **2016**, 41, 71-9	2.8	17
62	Characterization of fusion genes in common and rare epithelial ovarian cancer histologic subtypes. *Oncotarget*, **2017**, 8, 46891-46899	3.3	17
61	Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women. *Gynecologic Oncology*, **2019**, 153, 343-355	4.9	16
60	Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. *British Journal of Cancer*, **2020**, 123, 793-802	8.7	16
59	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. *PLoS ONE*, **2015**, 10, e0128106	3.7	15
58	Genome-Wide Study of Response to Platinum, Taxane, and Combination Therapy in Ovarian Cancer: In vitro Phenotypes, Inherited Variation, and Disease Recurrence. *Frontiers in Genetics*, **2016**, 7, 37	4.5	15
57	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. *Mayo Clinic Proceedings*, **2018**, 93, 307-320	6.4	14
56	Bevacizumab and improvement of progression-free survival (PFS) for patients with the mesenchymal molecular subtype of ovarian cancer.. *Journal of Clinical Oncology*, **2014**, 32, 5509-5509	2.2	14
55	Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers. *Oncotarget*, **2015**, 6, 35737-54	3.3	14
54	Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium. *Cancer Causes and Control*, **2017**, 28, 459-468	2.8	13
53	No association between a candidate TCF7L2 variant and risk of breast or ovarian cancer. *BMC Cancer*, **2009**, 9, 312	4.8	13
52	Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer. *International Journal of Cancer*, **2021**, 148, 307-319	7.5	13

51	Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo Clinic. *Gynecologic Oncology*, **2015**, 137, 77-85	4.9	12
50	Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. *Gynecologic Oncology*, **2015**, 136, 542-8	4.9	12
49	Mediation analysis of alcohol consumption, DNA methylation, and epithelial ovarian cancer. *Journal of Human Genetics*, **2018**, 63, 339-348	4.3	12
48	Assessment and implications of linkage disequilibrium in genome-wide single-nucleotide polymorphism and microsatellite panels. *Genetic Epidemiology*, **2005**, 29 Suppl 1, S72-6	2.6	12
47	BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis. *Journal of the National Cancer Institute*, **2020**, 112, 1190-1203	9.7	12
46	Population-based targeted sequencing of 54 candidate genes identifies as a susceptibility gene for high-grade serous ovarian cancer. *Journal of Medical Genetics*, **2021**, 58, 305-313	5.8	12
45	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. *Oncotarget*, **2016**, 7, 72381-72394	3.3	11
44	Molecular signatures of X chromosome inactivation and associations with clinical outcomes in epithelial ovarian cancer. *Human Molecular Genetics*, **2019**, 28, 1331-1342	5.6	11
43	A comprehensive gene-environment interaction analysis in Ovarian Cancer using genome-wide significant common variants. *International Journal of Cancer*, **2019**, 144, 2192-2205	7.5	11
42	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. *British Journal of Cancer*, **2018**, 118, 1123-1129	8.7	10
41	Intra-Gene DNA Methylation Variability Is a Clinically Independent Prognostic Marker in Women's Cancers. *PLoS ONE*, **2015**, 10, e0143178	3.7	10
40	Joint exposure to smoking, excessive weight, and physical inactivity and survival of ovarian cancer patients, evidence from the Ovarian Cancer Association Consortium. *Cancer Causes and Control*, **2019**, 30, 537-547	2.8	9
39	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. *PLoS ONE*, **2018**, 13, e0197561	3.7	9
38	Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. *Human Molecular Genetics*, **2016**, 25, 3600-3612	5.6	9
37	Testing Mediation Effects in High-Dimensional Epigenetic Studies. *Frontiers in Genetics*, **2019**, 10, 1195	4.5	9
36	Transcriptomic Characterization of Endometrioid, Clear Cell, and High-Grade Serous Epithelial Ovarian Carcinoma. *Cancer Epidemiology Biomarkers and Prevention*, **2018**, 27, 1101-1109	4	9
35	Genome-wide Analysis of Common Copy Number Variation and Epithelial Ovarian Cancer Risk. *Cancer Epidemiology Biomarkers and Prevention*, **2019**, 28, 1117-1126	4	8
34	Assessment of Multifactor Gene-Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors. *Cancer Epidemiology Biomarkers and Prevention*, **2016**, 25, 780-90	4	8

33	History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 1470-1473	4	8
32	Genetic Variants in Epigenetic Pathways and Risks of Multiple Cancers in the GAME-ON Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 816-825	4	7
31	Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. *American Journal of Epidemiology*, **2018**, 187, 366-377	3.8	7
30	An integrative approach to assess X-chromosome inactivation using allele-specific expression with applications to epithelial ovarian cancer. *Genetic Epidemiology*, **2017**, 41, 898-914	2.6	7
29	Prior oral contraceptive use in ovarian cancer patients: assessing associations with overall and progression-free survival. *BMC Cancer*, **2015**, 15, 711	4.8	7
28	A targeted genetic association study of epithelial ovarian cancer susceptibility. *Oncotarget*, **2016**, 7, 73814-9	3.3	7
27	Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2016**, 25, 446-54	4	6
26	Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium. *Human Genetics*, **2016**, 135, 137-54	6.3	6
25	Germline miRNA DNA variants and the risk of colorectal cancer by subtype. *Genes Chromosomes and Cancer*, **2017**, 56, 177-184	5	6
24	Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. *Modern Pathology*, **2021**, 34, 194-206	9.8	6
23	Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. *Gynecologic Oncology*, **2020**, 158, 702-709	4.9	5
22	Expression signature distinguishing two tumour transcriptome classes associated with progression-free survival among rare histological types of epithelial ovarian cancer. *British Journal of Cancer*, **2016**, 114, 1412-20	8.7	5
21	The Association of Peripheral Blood Regulatory T-Cell Concentrations With Epithelial Ovarian Cancer: A Brief Report. *International Journal of Gynecological Cancer*, **2017**, 27, 11-16	3.5	5
20	Comparison of tagging single-nucleotide polymorphism methods in association analyses. *BMC Proceedings*, **2007**, 1 Suppl 1, S6	2.3	5
19	Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. *Oncotarget*, **2017**, 8, 64670-64684	3.3	5
18	Genetic analyses of gynecological disease identify genetic relationships between uterine fibroids and endometrial cancer, and a novel endometrial cancer genetic risk region at the WNT4 1p36.12 locus. *Human Genetics*, **2021**, 140, 1353-1365	6.3	5
17	Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. *Cancer Medicine*, **2019**, 8, 2503-2513	4.8	4
16	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. *Oncotarget*, **2016**, 7, 69097-69110	3.3	4

LIST OF PUBLICATIONS

15	Subject level clustering using a negative binomial model for small transcriptomic studies. *BMC Bioinformatics*, **2018**, 19, 474	3.6	4
14	Genomic Analysis Using Regularized Regression in High-Grade Serous Ovarian Cancer. *Cancer Informatics*, **2018**, 17, 1176935118755341	2.4	3
13	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	3
12	Validated biomarker assays confirm ARID1A loss is confounded with MMR deficiency, CD8 TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas.. *Journal of Pathology*, **2021**,	9.4	3
11	Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies. *Journal of the National Cancer Institute*, **2021**, 113, 301-308	9.7	3
10	Leveraging global gene expression patterns to predict expression of unmeasured genes. *BMC Genomics*, **2015**, 16, 1065	4.5	2
9	Assessment of data transformations for model-based clustering of RNA-Seq data. *PLoS ONE*, **2018**, 13, e0191758	3.7	2
8	MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. *Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin*, **2021**,	5.1	2
7	DNA Methylation Profiles of Ovarian Clear Cell Carcinoma. *Cancer Epidemiology Biomarkers and Prevention*, **2021**,	4	2
6	Multi-tissue transcriptome-wide association study identifies eight candidate genes and tissue-specific gene expression underlying endometrial cancer susceptibility. *Communications Biology*, **2021**, 4, 1211	6.7	2
5	Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer. *Human Genetics and Genomics Advances*, **2021**, 2, 100042-100042	0.8	2
4	Identification of a Locus Near Associated With Progression-Free Survival in Ovarian Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2021**, 30, 1669-1680	4	2
3	Frequent POLE-driven hypermutation in ovarian endometrioid cancer revealed by mutational signatures in RNA sequencing. *BMC Medical Genomics*, **2021**, 14, 165	3.7	2
2	Circulating CD14 HLA-DR monocytic cells as a biomarker for epithelial ovarian cancer progression. *American Journal of Reproductive Immunology*, **2021**, 85, e13343	3.8	1
1	Generating real-world evidence from unstructured clinical notes to examine clinical utility of genetic tests: use case in BRCAness. *BMC Medical Informatics and Decision Making*, **2021**, 21, 3	3.6	1